Precede Biosciences Presents ESMO 2026 Data Revealing Biology Associated with Response and Resistance to PSMA-Directed Radioligand Therapy in Advanced Prostate Cancer
Baseline plasma profiling identified three molecular states previously characterized in tissue: androgen receptor (AR)-high/metabolic, stem/epithelial–mesenchymal transition (EMT), and AR-low/proliferative. The AR-high/metabolic group showed the most favorable outcome trends. Analysis of published gene sets corroborated these findings: higher stem-like and WNT signaling activity was associated with shorter time to next treatment, while higher AR signaling and luminal A activity was associated with longer time to next treatment. At progression, plasma-predicted expression of therapeutic targets, including PSMA, TROP2, SEZ6, CEACAM5 and DLL3, was evaluated relative to baseline, with predicted PSMA expression declining in 11 of 17 patients. These findings support investigation of treatment-sequencing strategies involving alternative PSMA-targeting modalities and therapies directed at other targets. BOSTON, Oct. 23, 2026 (GLOBE NEWSWIRE) — Precede Biosciences, a company powering next-generation precision medicine through its functional liquid biopsy platform, today announced new data being presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.